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ABSTRACT 
 Tissue engineered constructs with autologous adult stem cells capable of self-
repair and growth are highly desired replacements for diseased heart valves. However, 
the current approaches have inadequate mechanical properties to withstand in vivo 
implantation. Therefore, our group hypothesized that an in vitro environment of 
physiological intra-cardiac pressures and flow will stimulate stem cells to differentiate 
and remodel valvular scaffold constructs before implantation. 
 The group developed a pneumatic-driven conditioning system (Aim I) consisting 
of a three-chambered heart valve bioreactor, a pressurized compliance tank, a reservoir 
tank, one-way valves, pressure-retaining valves, and pressure transducers. The system 
can be sterilized using conventional autoclaving and ethylene oxide gas. The most novel 
feature is its ability to accommodate all clinically relevant sizes of stented or stentless 
biological, mechanical, or tissue engineered substitutes. A tissue derived heart valve 
substitute was used to test the bioreactor’s functional capabilities (Aim II) at 60 beats per 
minute. The tests resulted in excellent opening and closing of the valve, pulsatile flows 
reaching 1400 mL per minute, and aortic pressures reaching 100 mmHg. The bioreactor 
then tested tissue engineered heart valves (Aim III) made from decellularized and lightly 
cross-linked tissues. Two stentless porcine aortic heart valves were conditioned in the 
bioreactor for 21 days. The first was seeded with adipose-derived stem cells (valve 1) and 
the second with aortic endothelial cells (valve 2). The third valve was made of valve-
shaped fibrous sheets encasing a spongy collagen scaffold. It was seeded with human 
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bone marrow-derived stem cells (valve 3) and conditioned in the bioreactor for 8 days. 
After progressive adaptation, valves were tested at 60 beats per minute and 10 mL per 
stroke. Each experiment also included a static control. 
 The bioreactor created proper closing and opening of the heart valves and allowed 
for multiple mounting methods.  Results indicated successful cell seeding and attachment 
in valves 1, 2, and 3; noticeable intercellular alignment in valves 2 and 3; and stem cell 
differentiation in valve 3. Overall, the conditioning system provides a dynamic three-
dimensional cell culture setting designed to provide optimal physiological conditions for 
tissue engineered heart valve development over extended time periods. The group will 
continue to develop this approach to study multiple aspects of tissue engineered heart 
valve development and heart valve pathology.  
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
1.1 Cardiac Anatomy & Physiology 
 The heart has two double-chambered pumps. Figure 1 demonstrates the pressures 
and flow through these chambers. The right pump pushes blood through the lungs, where 
waste gases are exchanged for nutritional gasses. The left pump propels blood through 
the peripheral organs. Each group has two types of chambers. In each case, blood first 
enters the superior chamber, the atrium, which helps move blood through an 
atrioventricular valve into the ventricle. When these ventricles contract, blood propels 
through the pulmonary (right side) or ventricular (left side) valve and through the rest of 
the body. Following contraction, the pulmonary and aortic valves close to prevent blood 
flow back through the heart (Guyton and Hall, 2006). 
 
Figure 1: Blood flow through the heart. (Darling, ; Guyton and 
Hall, 2006) 
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 This cycle of opening and closing, sudden changes of pressure, and various other 
mechanical stresses make heart valves the most mechanically stressed tissues in the body 
(Bilodeau and Mantovani, 2006). This is especially true for the aortic valve, where the 
pressures are very high compared to the forces on the rest of the valves. These stresses 
often cause damage to the valves, in the form of microtears and calcific deposits. Since 
the aortic valve is the most stressed, it follows that it is also the most often diseased and 
replaced. Therefore, this project has focused on the aortic (Guyton and Hall, 2006). 
1.1.1 The Heart as a Pump 
 The pumping heart is a dynamic feedback system that changes its physical and 
chemical outputs according to the body’s needs. However, under average normal resting 
conditions, the left heart beats about 70 times per minute (bpm), ejecting 70 mL (stroke 
volume) of its left ventricular volume of 120 mL (end-diastolic volume) each beat. This 
results in a total of about 4.9 liters of blood flow per minute. The ventricles’ cyclic 
contractions create pressures that drive the blood through the circulatory system. When 
the left ventricle contracts, the pressure increases to about 120 mmHg. At this point, the 
aortic valve snaps shut and blood flows away from the heart along the pressure gradient. 
By the time the pressure in the aorta drops to about 80 mmHg, the left ventricle has 
begun its contraction to pump another bolus of blood and return the pressure to 120 
mmHg. Figure 2 shows the left ventricular volumes and pressures as described above 
(Guyton and Hall, 2006). 
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Figure 2: The cardiac cycle for the left heart. (Guyton and Hall, 2006) 
1.1.2 Aortic Valve Anatomy and Physiology 
 The physiological composition of a human aortic heart valve is optimized to 
withstand high physical stresses and respond to pressure changes during diastolic and 
systolic stages of the cardiac cycle. The tricuspid valve is constructed with very strong, 
yet very pliable fibrous tissue with three heterogeneous leaflets attached to an annular 
ring (Fong, Shin'oka et al., 2006). These leaflets open during systole and press against the 
aortic root wall. When they snap close at the start of diastole they meet to create a seal 
that can prevent backflow even with the 100 mmHg transvalvular pressure difference. 
This cycle maintains efficient unidirectional flow with each heart beat. 
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 Valve leaflets consist of three layers of tissue that together have the necessary 
biomechanical properties to withstand cyclic loading. Table 1 displays each layer’s 
composition and function. Figure 3 shows a view of the aortic valve and a cross-sectional 
view of a cusp. 
Table 1: Composition and function of each valve layer. 
Layer Matrix Composition Function 
Top Fibrosa 
Densely packed circumferencially 
aligned collagen; elastin 
Maintain durability and stiffness 
to withstand 80 mmHg pressure 
gradient 
Middle Spongiosa 
Loosely arranged collagen; 
glycosaminoglycans 
Allows shearing between the 
ventricularis and the fibrosa 
during valve cycle 
Bottom Ventricularis 
Densely packed collagen; radially 
aligned elastin 
Maintains valve resilience, allows 
stretch in response to pressure 
changes 
(Vesely, 2004; Schoen, 2005; Simionescu, 2006) 
 
 
Figure 3: Aortic valve anatomy. a) aortic valve dissected for viewing (LifeART). b) cross section of a 
cusp, showing the three layers present (Vesely, 1998). 
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1.1.3 Aortic Valvular Disease 
Aortic valvular heart disease is classified into two main types: 1) stenosis or 2) 
regurgitation. There are various causes for each of these problems, but the final outcome 
is the same. Patients suffering from valvular heart disease will eventually need a heart 
valve replacement (Guyton and Hall, 2006). 
In aortic stenosis, the left ventricle fails to empty adequately following 
contraction because the aortic valve does not open properly, creating a reduction in the 
valvular orifice. In aortic regurgitation, blood flows back into the left ventricle after 
contraction because the aortic valve does not close properly (Guyton and Hall, 2006). 
Valvular heart disease can be a congenital defect such as improper valve size, 
malformed leaflets, or an irregularity in the way the leaflets are attached. It may also be 
caused by damage acquired after birth such as calcific deposits, changes in the structure 
of the valve, or infections like infective endocarditis and rheumatic fever. Both stenosis 
and regurgitation lead to a reduction in the net stroke volume output of the heart, causing 
it to work harder to pump the same amount of blood through the body (Clinic). 
Eventually, the diseased valve must be replaced. 
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1.2 Heart Valve Bioreactors 
 Bioreactors can be defined “as devices in which biological and/or biochemical 
processes develop under closely monitored and tightly controlled environmental and 
operating conditions (e.g. pH, temperature, pressure, nutrient supply, and waste removal)” 
(Martin, Wendt et al., 2004). Requirements for such bioreactors and examples of previous 
aortic valve bioreactors are discussed below. 
1.2.1 Bioreactor Requirements 
 Freed (Freed and Vunjak-Novakovic, 2000) says that a bioreactor must be able to 
perform at least one of the following five functions: (1) establish a uniform distribution of 
cells on a three-dimensional (3D) scaffold, (2) maintain the desired concentration of 
gases and nutrients in the culture medium, (3) provide efficient mass transfer to the 
growing tissue, (4) expose developing tissue to physical stimuli, and (5) provide 
information regarding the formation process of 3D tissues, which originate from the 
isolated cells. This project focused on functions 2, 3, and 4 of Freed’s declared functions. 
 One of the most important controls of a bioreactor is to supply an adequate 
amount of oxygen to a 3D tissue construct. Other biochemical factors, such as carbon 
dioxide and wastes also require adequate transport. In conventional cell culture, this is 
most often done by creating a large liquid to sterile air interface to facilitate the diffusive 
transport of oxygen. In a bioreactor, where the volume of culture medium present is much 
larger than in standard cell culture, additional methods must be used. These methods 
range from a sterile filter open to the external environment in combination with flow of 
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the culture medium (Dumont, Yperman et al., 2002) to coiling gas-permeable tubing 
inside a culture medium reservoir (Warnock, Konduri et al., 2005). 
 Physical stimuli such as tension, compression, shear stresses, pressure, 
temperature, and pulsatile flow of culture medium improve the structure and mechanical 
properties of engineered tissues (Rabkin and Schoen, 2002; Barron, Lyons et al., 2003). 
These mechanical forces have an integral part in regulation of cell phenotype and growth 
and the repair or degradation of tissues (Rabkin and Schoen, 2002). Control of trans-
valvular pressure, pulsatile forces, flow rate, frequency, stroke rate, and stroke volume 
are all important design parameters of bioreactor to ensure that the necessary physical 
stimuli are integrated into the design (Barron, Lyons et al., 2003). 
1.2.2 Current Bioreactors 
 Current heart valve bioreactors are designed to test a single valve in vitro at 
different levels of pulsatile flow under controlled conditions in a standard humidified 
incubator at 37°C and 5% CO2 Figure 4.  shows the common main components of aortic 
valve bioreactors, which include a reservoir, mechanical valve, pump, processing 
chamber, compliance chamber, resistance, and a filter (Barron, Lyons et al., 2003). This 
schematic gives one representative layout of these components, but many bioreactors in 
use today have variations on placement, type, and extent of use of these components. 
Most bioreactors have control over parameters such as flow, pH, and stroke volume and 
can change those parameters as desired to create varying environments for the valves. 
One use of the controllable parameters is progressive adaptation, where increasing 
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amounts of mechanical stimuli are applied to aid strengthening of the tissue construct and 
prevent immediate failure upon implantation. 
 There are currently numerous individual laboratories across the country using 
heart valve bioreactors. Many reviews (Freed and Vunjak-Novakovic, 2000; Rabkin and 
Schoen, 2002; Ratcliffe and Niklason, 2002; Barron, Lyons et al., 2003; Martin, Wendt et 
al., 2004; Martin and Vermette, 2005; Bilodeau and Mantovani, 2006) contain extensive 
comparison and assessment of the variations between them. The bioreactors range in 
design, complexity, and function, performing at various levels and accuracy. Valve 
mounting methods and modes of assembly vary, often with little options or ability to 
accommodate abnormal valve shapes. While many bioreactors are very powerful and can 
achieve high pressurization, none have been found to be able to subject valves to the wide 
range of synergistic physiological stresses that would be present if the valve were 
implanted into the body (Bilodeau and Mantovani, 2006). 
 Overall, much progress has been made in the area of heart valve bioreactors. 
However, there is still room for improvement. 
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Figure 4: Schematic diagram of a model pulsatile flow bioreactor. (Barron, Lyons et al., 2003) 
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CHAPTER 2: PROJECT APPROACH 
2.1 Overview 
 Existing heart valve replacements provide major improvements in cardiac 
function and life expectancy but have significant limitations and require either lifelong 
anticoagulation therapy for the mechanical valves or surgical replacement within 15-20 
years for tissue derived valves. Thus, tissue engineered constructs with autologous adult 
stem cells capable of self-repair and growth are highly desired replacements for diseased 
heart valves. In response to the current approaches’ inadequate mechanical properties 
upon in vivo implantation, our group hypothesizes that an in vitro environment of 
physiological intra-cardiac pressures and flow will stimulate stem cells to differentiate 
and remodel valvular scaffold constructs before implantation. 
 The goal of this master’s project has been to develop, build, and test a pulsatile 
bioreactor that will cause a valve to cyclically open and close and will provide the 
physiological intra-cardiac pressures and flow to condition tissue engineered heart valves. 
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2.2 Specific Aims 
 This work has three distinct parts: 1) designing and building a heart valve 
bioreactor, 2) testing the heart valve bioreactor’s capabilities as a pump, and 3) using the 
heart valve bioreactor to test tissue engineered heart valves. 
2.2.1 Aim I: Design and Build a Heart Valve Bioreactor 
 The desired heart valve bioreactor had three fundamental functional requirements: 
That 1) the valve open and close cyclically due to a change in trans-valvular pressure, 2) 
the pressure be adjustable to simulate intra-cardiac pressures, and 3) the fluid in the 
culture system circulate to achieve nutrient and waste transport and create appropriate 
sheer stresses on the valve surface. All materials were to be non-toxic and non-
degradable. The system was to maintain sterility and visibility of the operation of the 
heart valve. 
 Evaluative design methods provided the basis for the bioreactor’s systematic 
design. First, we identified the customers and their wants. Then we identified and 
evaluated the competition and developed means to evaluate the customers’ wants. After 
setting minimum and optimal values for each desired capability, we identified any 
conflicting effects of improving outcomes. After completing the design, the drawings 
were drafted, the manufacturing was accomplished, and the system was tested. 
2.2.2 Aim II: Test the Heart Valve Bioreactor’s Capabilities as a Pump 
 The desired environmental conditions of the bioreactor as a pump include 1) 
aortic systolic/diastolic pressures reaching at least 120/80 mmHg, 2) flow rates reaching 
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5000 mL/min, 3) stroke rate exceeding 60 beats per minute, 4) oxygen and carbon 
dioxide levels high enough to support cell and tissue growth, and 5) repeatable conditions. 
2.2.3 Aim III: Use the Heart Valve Bioreactor to Test Tissue Engineered 
Heart Valves 
 A bioprosthetic heart valve was used to test the conditioning system under both 
light and rigorous conditions. We used flow meters and pressure transducers to evaluate 
the bioreactor’s capabilities as a pump in according to the desired conditions. 
 The desired use of this bioreactor is to create an in vitro environment of 
physiological intra-cardiac pressures and flow for the conditioning and testing of tissue 
engineered heart valves. 
 The system’s ability to sustain a freshly collected, living heart valve (valve 1) was 
first tested. After that, the bioreactor tested tissue engineered heart valves made from 
decellularized and lightly cross-linked tissues. Two stentless porcine aortic heart valves 
were tested in the bioreactor for 21 days. The first was seeded with rat adipose-derived 
stem cells (valve 2) and the second with porcine aortic endothelial cells (valve 3). The 
last valve was made of valve-shaped fibrous sheets encasing a spongy collagen scaffold. 
It was seeded with human bone marrow-derived stem cells (valve 4) and conditioned in 
the bioreactor for 8 days. 
 Cellular assays including Live/DEAD, MTS, Diff-Quick, SEM, H&E staining, 
and DAPI staining were used to evaluate cell viability and stem cell differentiation.  
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Bioreactor Design 
 The bioreactor’s development was approached as a design project. As such, 
certain formal methods of design were used to determine the desired qualities of the 
system and those qualities’ desired values. The design process closely followed Dym and 
Little’s (2004) design book Engineering Design: A Project-Based Introduction. These 
methods can also be documented using a quality function development (QFD) chart. The 
QFD development process can be found in The Mechanical Design Process
3.1.1 Customer and Design Goals (Who, What, & Who vs. What) 
 by Ullman 
(2003). The following subsections detail the use of these design processes. 
 A fundamental step in any design project is to identify the customers, then move 
on to what the customers desire (attributes) from the device. The primary customer for 
this project was the principle investigator of the Biocompatibility and Tissue 
Regeneration Laboratory (BTRL), Dr. Dan Simionescu. The initial client statement 
provided was to “Create a bioreactor to test and condition about 10 replacement heart 
valves.”  
 Expansion of the project revealed additional customers in the form of other lab 
members. These included Mary E. “Betsy” Tedder, Ting-Hsien “Tom” Chuang, and Dr. 
Agneta Simionescu. Through interviews, a customer questionnaire, and a review of 
current devices, a comprehensive design attributes list was compiled and divided into 
objectives, functions, and constraints. After pruning and grouping the objectives list, pair-
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wise comparison charts were used to rank the importance of each objective for each user. 
These were combined to form a comprehensive ranked objectives list, which helped 
develop the objectives tree seen in Figure 5. Using these ranked objectives and a further 
understanding of the customers’ desired attributes, an updated client statement was 
developed: 
 
“Create a bioreactor to simultaneously test and condition 3-6 replacement 
heart valves under physiological mechanical and nutritional conditions. 
The vital conditions of the aforementioned environment include cyclic 
opening and closing of the valve, aortic systolic/diastolic pressures 
reaching 
 The design documentation used to identify and develop the customers and 
objectives can be found in 
at least 120/80 mmHg and oxygen and carbon dioxide levels high 
enough to support the growth of the cells and tissues. Flow rates reaching 
5000 mL/min and a stroke rate exceeding 60 beats per minute are also 
desired. This bioreactor should be consistent in its repeatability of 
conditions between cycles and over the life of the bioreactor. All materials 
used must be non-toxic and non-degradable. Sterility and visibility of the 
operation of the heart valves should be maintained.” 
 
 
 The design was based upon this updated client statement and the previously 
mentioned ranking of objectives. Reviewing these items periodically ensured that the 
design continued to be what the customers desired. 
Appendix A: Design Documentation. 
  
 15 
 
 
Figure 5: Objectives tree  
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3.1.2 Current Devices’ Capabilities (Now & Now vs. What) 
 Section 1.2.2 described typical existing heart valve bioreactors. Some of these 
bioreactors were extremely similar and some were very different from the desired system. 
The desired attributes from all the designs were considered, but only the most closely 
related devices were further investigated. Every device was ranked for each of the design 
attributes. Those rankings then summarized the most effective means currently 
implemented to meet the desired attributes. After this evaluation, it was then possible to 
investigate methods of improvement for each design attribute as necessary. 
3.1.3 Measurement, Evaluation, and Desired Values (How, How vs. What, & 
How Much) 
 The next step of the design process was to determine how each desired attribute 
would be measured (metrics) and the units in which those measurements could be 
recorded. Some were fairly obvious, such as desired pressure being measured in mmHg, 
while others were less obvious, such as sterilizability being measured in hours taken to 
sterilize completely.  
 After determining the metrics for each attribute, a range of acceptable values was 
developed. This range extended from levels at which it was expected that the customer 
would be delighted by the outcome to levels at which it was expected that the customer 
would be disgusted by the outcome. For example, for maximum attainable flow rate, 
disgusted and delighted values of 500 mL/min and 1000 mL/min, respectively were set. 
If the final design provided a maximum flow rate less than 500 mL/min, it was expected 
that the customers would not be satisfied. However, if the final design provided a 
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maximum flow rate of more than 1000 mL/min, it was expected that the customers would 
be fully satisfied. 
3.1.4 Synergism and Conflictions (How vs. How) 
 Finally, to give a better understanding of the design, the ways in which improving 
one attribute would affect the other attributes was assessed. Some had positive 
interactions while others had negative interactions and a balance of improvements had to 
be made. More often, improving one attribute had no affect on the performance of other 
attributes. 
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3.2 Bioreactor Capabilities Testing Using a Bioprosthetic Valve 
 To demonstrate the achievement of the heart valve bioreactor’s two fundamental 
functional requirements, “aortic” pressure, “ventricular” pressure, and fluid flow were 
tested. All tests used double-distilled water and a bioprosthetic heart valve (BHV). The 
BHV was an expired porcine glutaraldehyde fixed stented aortic valve replacement, 
25mm Toronto SPV Valve from St. Jude Medical. 
3.2.1 Pressure 
 The end diastolic- and end systolic- left ventricular and aortic pressure were 
determined by obtaining pressure readings from each of the aortic and ventricular 
chambers of the bioreactor. Pressure transducers (Cole-Parmer, K-68075-16) were 
mounted and a data acquisition system (DAQ) (OMEGA, OMB-DAQ-55) took readings 
at 180 Hz. The aortic pressure transducer was approximately 7.5 cm above the valve and 
the ventricular pressure transducer was approximately 8.0 cm below the valve. As per 
normal settings, the ventilator was set to have an inspiration time of 50%, pause time of 
0%, working pressure of 110 cmH2
Figure 6
O, 60 bpm, and an actual inspiration tidal volume of 
138±2mL. The total volume of fluid in the system was estimated to be 1,600 mL. This 
fluid was distributed between the bioreactor and two reservoirs: one to be pressurized and 
one to serve for gas exchange. The setup of the system can be seen in .  
 Values of pressure were recorded under no pressurization, after an initial 
pressurization of the top reservoir using compressed air, and after a second pressurization 
of the top reservoir. 
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Figure 6: Assembly of bioreactor system for pressure testing. 
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3.2.2 Flow 
 Cyclic flow volume was determined using one flow meter (Cole-Parmer catalog #: 
K-32550-07) on each of the two outlet lines from the aortic chamber going to the 
reservoir. The top and bottom fluid levels with respect to the bottom of the bioreactor 
were 13cm and 9.5cm, respectively. As per normal settings, the ventilator was set to have 
an inspiration time of 50%, pause time of 0%, and working pressure of 108 cmH2O.  
 Following one minute of cyclic flow at 60 beats per minute (bpm), the values 
were recorded to determine the flow per minute and stroke volumes attainable at these 
conditions. The actual inspiration tidal volume was adjusted while keeping all other 
variables constant to determine flow capabilities. Each level of actual inspiration tidal 
volume was repeated two times (n=2) and the readings averaged. 
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3.3 Experimental Methods 
 The following protocols were used in the experimentation, testing, and analysis of 
valves in the bioreactor. 
3.3.1 Porcine Aortic Valve Collection and Cleaning 
 Fresh porcine hearts, with intact ascending aorta, were collected from a local 
USDA approved abattoir, Snow Creek Meat Processing, Seneca, SC. The aortic valves 
were dissected from the hearts in a section of tissue including the aortic root, aortic valve, 
adjacent portion of the mitral valve, and excess muscular tissue on the opposite side as 
the mitral valve. Valves were collectively stored in a 500mL bottle of un-buffered, sterile 
saline with 2% antibiotics/antimycotics over ice during transportation to the laboratory. 
The valves were then cleaned over ice on the lab bench. To clean the valves, the tissue 
was trimmed of excess fat, the aortic root was trimmed to a length of about one inch, the 
mitral valve was trimmed of excess material, and the muscle was trimmed to a thickness 
of less than one mm adjacent to the endocardium. 
3.3.2 Tissue Decellularization 
 To minimize the immune responses, the porcine aortic valves were decellularized 
by removing cellular components and Gal-α (1,3) Gal, a porcine specific antigen. This 
was performed via steps of hypotonic shock using double distilled water (ddH2O), 
extraction of cell fragments using 0.05M NaOH then decellularization solution (0.05% 
SDS, 0.5% Triton X-100, 0.5% Na-Deoxycholate, and 0.2% EDTA in 10mM TRIS, pH: 
7.5), removal of nucleic acids using DNAse/RNAse, and sterilization using 70% EtOH. 
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Materials: 
• Heart valves 
• ddH2
• sterile ddH
O 
2
• 70% EtOH 
O 
• Sterile 1x PBS 
• Sterile suture 
• 10mM TRIS (2.42g TRIS in 2L ddH2
• 0.05 M NaOH (2g NaOH in 1L 10mM TRIS) 
O at pH:7.4-7.5) 
• Decellularization solution (in 1 Liter 10mM TRIS) 
o 0.05% SDS (Sodium Dodecyl Sulfate) (0.5g) – wear a breathing mask 
o 0.5% Triton X-100 (5 mL) 
o 0.5% Deoxycholic Acid, Sodium Salt (5g) – wear a breathing mask 
o 0.2% EDTA (Ethylenediaminetetra-acetic acid) (2g) 
• DNAse/RNAse (deoxyribonuclease/ribonuclease) (in 1 Liter PBS) 
o 1.015g MgCl
o 0.18mg DNAse (360 milliunits/ml) 
2 
o 3.7mg RNAse (360 milliunits/ml) 
 
Methods: 
1. Rinse valves with ddH2
2. Incubate valves in 
O 
ddH2
3. Incubate valves in 
O overnight at 4°C 
0.05 M NaOH
4. Rinse valves w/ddH
 2 hours at room temperature under agitation 
2
5. Sterilize valves in 
O (3x) 
70% EtOH
6. Rinse valves w/ddH
 20 minutes at room temperature under agitation 
2
7. Incubate in 
O (3x) 
decellularization solution
8. Rinse with ddH
 overnight at room temperature under agitation 
2
9. Sterilize valves in 
O (5-10x) 
70% EtOH
10. Rinse valves with ddH
 20 minutes at room temperature under agitation 
2
11. Incubate valves in 
O (3x) 
ddH2
12. Incubate in 
O 2 hours at room temperature under agitation 
RNAse/DNAse
13. Rinse with ddH
 overnight at room temperature under agitation 
2
14. Suture coronary arteries closed to aid future cell seeding 
O (3x) 
15. Sterilize valves in 70% EtOH
---- STERILE CONDITIONS: INDIVIDUAL, STERILE, SPECIMEN-CUPS ---- 
 overnight at room temperature under agitation 
16. Rinse with sterile PBS (3x) 
17. Incubate valves in sterile ddH2
18. Follow with tissue fixation 
O 2 hours at room temperature under agitation 
3.3.3 Tissue Fixation 
 Heart valve scaffolds were fixed to cross-link the proteins in the valve. They were 
treated overnight at room temperature under agitation with 0.075% penta-galloyl glucose 
(PGG) in 50mM dibasic sodium phosphate buffer in saline with 20% isopropanol, pH 5.5. 
The materials and methods follow. 
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Materials (for 500mL): 
• Decellularized heart valves 
• ddH2
• 70% EtOH 
O 
• Sterile 1x PBS 
• Saline (3.6g NaCl in 400 mL ddH2
• 0.075% PGG (Slowly add 400 mL phosphate buffer to 100mL PGG solution and run through 0.22 
µM sterile filter system) 
O) 
o Phosphate Buffer - 50mM Na2HPO4 (2.84g Na2HPO4
o 0.375g PGG dissolved in 100 mL isopropanol 
 in 400 mL saline, pH: 5.5) 
o 0.22 µM sterile filter system 
 
Methods: 
1. Rinse with sterile PBS (3x) 
2. Incubate valves in sterile 0.075% PGG
1. Rinse with sterile PBS (3x) 
 overnight at room temperature under agitation 
2. Sterilize valves in 70% EtOH
3. Rinse with sterile PBS (3x) 
 20 minutes at room temperature under agitation 
4. Follow with cell seeding or store in sterile 0.02% NaN
3.3.4 Neutralization and Cellular Seeding 
3 
The valve scaffolds were incubated at least 3 hours at room temperature in sterile 
Delbecco’s Modified Eagle Medium with 50% fetal bovine serum and 2% 
antibiotics/antimicotics to neutralize any phenolic groups from the PGG that may have 
been left after fixation. After aspirating the neutralization solution, the valves were stood 
upright in individual specimen cups and seeded with the appropriate number of cells in 
200 µL of cell culture media for each cusp. Additional cell culture media was placed on 
the valves following mounting into the bioreactor. 
3.3.5 Live/DEAD® staining 
The LIVE/DEAD® Viability/Cytotoxicity Assay Kit (Molecular Probes) is a two-
color fluorescence assay used to stain cells on the surface of the cusps. Intracellular 
esterase activity distinguishes live cells via the enzymatic conversion of calcein AM to 
calcein, which intensely fluoresces green in live cells. The kit also uses EthD-1, which 
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enters cells with damaged membranes and fluoresces upon binding to nucleic acids, 
indicating dead cells upon its bright red fluorescence. 
The assay was prepared as directed and placed on cusps in a six-well plate. After 
the incubation time in the dark, the samples were imaged with the fluorescence 
microscope (Invitrogen, 2005). 
 
Materials (for 10mL): 
• 1x PBS 
• Six-well culture plates 
• Live/DEAD® Viability/Cytotoxicity Assay Solution (Molecular Probes) (Vortex the EthD-1 and 
PBS, then add calcein and vortex) 
o 20 µL EthD-1 
o 5 µL 4mM calcein 
o 10mL 1x PBS 
 
Methods: 
1. Dissect valve leaflet from the valve 
2. Rinse leaflet with PBS (1x) 
3. Place leaflet in a well of the six-well culture plate 
4. Add ~3mL stain to each well 
5. Incubate in Live/DEAD® solution
6. Image using FITC and Texas Red filters to examine the cells 
 20 minutes at 37°C in the dark 
3.3.6 MTS 
 MTS is the common name for the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay. It is a colorimetric method used to determine the number of viable 
cells present in culture. The reagent combines a tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt; MTS] and an electron coupling reagent (phenazine ethosulfate; PES) to form a 
stable solution. The compound is added to the cells, where it is bioreduced into a colored 
formazen product by dehydrogenase enzymes in metabolically active cells. The number 
of living cells is directly proportional to the quantity of formazan product as measured by 
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the absorbance at 490 nm (Promega, 2007). For this assay, the reagent was added to the 
cell culture, incubated for at least one hour, and the absorbance read at 490nm with a 96-
well plate reader. 
3.3.7 Diff-Quick 
 Diff-Quick staining is a type of Romanowski stain based on a combination of 
eosin and methylene blue. It was originally designed to incorporate pink cytoplasmic 
staining with blue nuclear staining and fixation as a single step. For this assay, the leaflet 
was fixed in the Diff-Quick fixative for 30 seconds, and then rinsed with PBS. Following 
fixing, the tissue was stained in Diff-Quick solution II for 10 seconds, rinsed with PBS, 
counterstained with Diff-Quick solution I for 10 seconds, rinsed with PBS, and viewed 
under the light microscope. 
3.3.8 Scanning Electron Microscopy 
 Scanning electron microscopy was used to image the cusp surface for a three-
dimensional view of any cells present. After careful dissection from the valves, the cusps 
were placed and stored in Karnovsky’s fixative (2.5% glutaraldehyde, 2% formaldehyde 
in 0.1 cacodylate, pH=7.4). Following dehydration with ethanol and coating with gold, 
the samples were imaged using the Hitachi S4800. 
3.3.9 Hematoxylin and Eosin Sections 
 Hematoxylin & Eosin (H&E) staining is a popular staining method in histology. It 
uses the basic dye, hematoxylin, to color basophilic structures, such as those containing 
nucleic acids like the cell nucleus, a blue-purple hue. The acidic dye, eosin, colors 
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eosinophilic structures, such as cytoplasm and some extracellular matrix products, bright 
pink (Ross, Kaye et al., 2003). 
 Following fixation in 10% formalin, cusps were cut in half, embedded in paraffin 
wax, sectioned, and stained according to the following routine H&E staining method. 
Orientation of the sections was in the radial direction, crossing (vs. aligning with) the 
collagen bundles. 
 
1. Xylene  ---------------------- 10 dips 
2. Xylene  ----------------------- 5 min 
3. 100% EtOH ----------------- 10 dips 
4. 100% EtOH ----------------- 1 min 
5. 95% EtOH ------------------ 10 dips 
6. 95% EtOH ------------------ 1 min 
7. Running Water -------------Till Clear 
8. Distilled Water ------------- 1 min 
9. Hematoxylin --------------- 5 min 
10. Running Water -------------Till Clear 
11. Clarifier ---------------------10-15 dips 
12. Running Water -------------Till Clear 
13. Bluing ----------------------- 1 min 
14. Running Water ------------- 30 sec 
15. 95% EtOH ------------------ 10 dips 
16. Eosin ------------------------ 45 sec 
17. 95% EtOH ------------------ 10 dips 
18. 95% EtOH ------------------ 10 dips 
19. 100% EtOH ---------------- 10 dips 
20. 100% EtOH ---------------- 10 dips 
21. 100% EtOH ---------------- 10 dips 
22. Xylene  ---------------------- 10 dips 
23. Xylene  ---------------------- 5 min 
3.3.10 DAPI Sections 
 DAPI (4'-6-Diamidino-2-phenylindole) is a florescent stain that will pass through 
an intact cell membrane and bind strongly to dsDNA. Thus, it is used extensively in 
fluorescence microscopy to stain both live and fixed cells with a corresponding emission 
of bright blue fluorescence.(Invitrogen, 2006) 
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 After performing routine H&E staining, DAPI staining helped validate the 
presence of nucleic acids that were difficult to distinguish. Each fixed and paraffin-
embedded section was brought back to water according to the following steps and stained 
directly on the slide.  
 
1. Xylene  ---------------------- 10 dips 
2. Xylene  ---------------------- 5 min 
3. 100% EtOH  ---------------- 10 dips 
4. 100% EtOH  ---------------- 1 min 
5. 95% EtOH ------------------ 10 dips 
6. 95% EtOH ------------------ 1 min 
7. Running Water -------------Till Clear 
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3.4 Heart Valve Experimentation  
 The experimental usefulness of the bioreactor was tested using a living valve; 
decellularized, fixed, and seeded valves; and a tri-layered valve made from pericardium 
and scaffolding. In all, fifteen experiments were performed. These consisted of the 
following four types; one set of results will be shown for each type. 
3.4.1 Valve 1: Living Valve – 7 Days 
Valve preparation 
 Valves were collected from Snow Creek Meat Processing, Seneca, SC and 
cleaned as described in section 3.3.1. Modifications to the above protocol consist of 
cleaning the valves in the sterile hood instead of on the lab bench. 
Bioreactor conditions 
 Following cleaning, the living valve was mounted in the bioreactor in DMEM 
with 10% fetal bovine serum and 1% antibiotics/antimycotics. That valve was then tested 
at 60 bpm and 60 mL of air per stroke for seven days inside the incubator at 37°C and 5% 
CO2
Analysis 
. A static control valve was kept in a specimen cup in the incubator, next to the 
bioreactor. 
 After dissection, the cusps of the valves were cut away from the valve wall and 
the MTS, Live/DEAD and Diff-Quick assays were performed as listed in Table 2. 
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Table 2: Experimental conditions & assays for living valve experiment (3.4.1). 
ID Cusp Number of Days 
Conditioning specifications 
Assay Performed beats 
per 
minute 
stroke 
volume 
(mL) 
°C 
% 
CO
2 
V
al
ve
 1
 
1-
15
0-
Li
vi
ng
 1 a 
7 60 15 37 5 
Live/Dead 
1 b DiffQuick 
2 a Live/Dead 
2 b MTS 
3 a Live/Dead 
3 b MTS 
V
al
ve
 2
 
1-
15
0-
St
at
ic
 1 a 
7 0 0 37 5 
Live/Dead 
1 b DiffQuick 
2 a Live/Dead 
2 b MTS 
3 a Live/Dead 
3 b MTS 
 
3.4.2 Valve 2: Endothelial Cell Seeded Valve – 21 Days 
Valve preparation 
 Eight valves were collected from Snow Creek Meat Processing, Seneca, SC and 
cleaned as described in section 3.3.1. Following decellularization (3.3.2 – Modifications 
include step 2: Incubate valves in ddH2
3.3.3
O overnight at room temperature under agitation) 
and tissue cross-linking ( ), the valves were stored in 0.02% NaN3
Table 3
. Four valves (see 
) were used for this experiment as selected by visual opening and closing between 
step 14 and 15 in section 3.3.2: Tissue Decellularization. These valves included a time 
zero day, non cell-seeded valve (T0DC), a time zero day, cell-seeded valve (T0C), a time 
21 day static control (T21S), and a time 21 day dynamic test valve (T21D). 
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Cellular specifications 
 After seven days of storage, the four selected valves were rinsed and stored in 
sterile saline for two days at 4°C to remove any residual NaN3
Bioreactor conditions 
. This was followed with 
neutralization and cell seeding (3.3.4). 1E5 porcine aortic endothelial cells at passage 6 
were seeded per cusp. MCDB with 10% fetal bovine serum and 2% 
antibiotics/antimycotics without cells was used as a control for valve T0DC. 
 The test valve was mounted in the bioreactor and progressive adaptation over the 
course of 20 hours was used to bring the pumping conditions to 60 bpm and 10mL per 
stroke. DMEM with 10% fetal bovine serum and 2% antibiotics/antimycotics was used 
and changed every seven days for all samples. Of note is that after the first seven days, 
the culture media in the bioreactor began to appear cloudy. The cell culture media in the 
system was changed as soon as possible after noticing this. Cloudiness did not return for 
the remainder of the experiment. Static controls as listed in Table 3 were placed in 
specimen cups in the incubator next to the bioreactor at 37°C and 5% CO2
Analysis 
. 
 After one night in the incubator and dissection of cusps from the valve wall, the 
cusps of valves T0C and T0DC were analyzed according to the assays listed in Table 3. 
After 21 days, the cusps of valves T21D and T21S were analyzed according to the assays 
listed in Table 3. 
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Table 3: Experimental conditions & assays for endothelial cell experiment (3.4.2). 
ID Cusp Cells Number of Days 
Conditioning specifications 
Assay Performed beats per 
minute 
stroke 
volume 
(mL) 
°C % CO2 
V
al
ve
 1
 
2-
08
3-
T0
C
 1 a 1E5 
over-
night 0 0 37 5 
SEM 1 b 
2 a 1E5 DNA (not performed) 2 b Protein (not performed) 
3 a 1E5 Live/Dead H&E DAPI 3 b 
V
al
ve
 2
 
2-
08
3-
T0
D
C
 1 a 0 
over-
night 0 0 37 5 
SEM 1 b 
2 a 0 DNA (not performed) 2 b Protein (not performed) 
3 a 0 Live/Dead H&E DAPI 3 b 
V
al
ve
 3
 
2-
08
3-
T2
1D
 1 a 1E5 
21 60 10 37 5 
SEM 1 b 
2 a 1E5 DNA (not performed) 2 b Protein (not performed) 
3 a 1E5 Live/Dead H&E DAPI 3 b 
V
al
ve
 4
 
2-
08
3-
T2
1S
 1 a 1E5 
21 0 0 37 5 
SEM 1 b 
2 a 1E5 DNA (not performed) 2 b Protein (not performed) 
3 a 1E5 Live/Dead H&E DAPI 3 b 
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3.4.3 Valve 3: Adipose-derived Stem Cell Seeded Valve – 21 Days 
 This experiment was performed in collaboration with Dr. Aggie Simionescu and 
Christopher Albers. 
Valve preparation 
 Valves were collected from Snow Creek Meat Processing, Seneca, SC and 
cleaned as described in section 3.3.1. Decellularization (3.3.2) and tissue cross-linking 
(3.3.3) followed. Conditions for the two valves used for this experiment can be seen in 
Table 4. 
Cellular specifications 
 After neutralization the valves were seeded (3.3.4) with rat adipose derived stem 
cells. 5E4 cells/cm2
Bioreactor conditions 
 were seeded in each cusp. 
 The test valve was mounted in the bioreactor in DMEM with 10% fetal bovine 
serum and 1% antibiotics/antimycotics and progressive adaptation was used to bring the 
pumping conditions to 60 bpm and 10mL per stroke. A static control was placed in a 
specimen cup in the incubator next to the bioreactor at 37°C and 5% CO2
Analysis 
. Media was 
changed every seven days for all samples. 
 After 21 days and dissection of cusps from valve walls, the cusps of valves T21D 
and T21S were analyzed according to the assays listed in Table 4.  
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Table 4: Experimental conditions & assays for stem cell experiment (3.4.3). 
ID Cusp Number of Days 
Conditioning specifications 
Assay Performed beats 
per 
minute 
stroke 
volume 
(mL) 
°C 
% 
CO
2 
V
al
ve
 1
 
2-
11
8-
T7
21
D
 1 a 
7 60 10 37 5 
Live/DEAD 
1 b H&E DAPI 
2 a Live/DEAD 
2 b H&E DAPI 
3 a Live/DEAD 
3 b H&E DAPI 
V
al
ve
 2
 
2-
11
8-
T2
1S
 1 a 
7 0 0 37 5 
Live/DEAD 
1 b H&E DAPI 
2 a Live/DEAD 
2 b H&E DAPI 
3 a Live/DEAD 
3 b H&E DAPI 
 
3.4.4 Valve 4: Tri-layered Tissue Engineered Heart Valve – 8 Days 
 This experiment was performed in collaboration with Dr. Dan Simionescu and 
Mary E. “Betsy” Tedder. 
Valve preparation 
 Porcine pericardium and porcine pulmonary artery from 2+ year pigs were 
received from Animal Technologies, Inc., Tyler, Tx, and cleaned of all tissue and 
extraneous fat/loose connective tissue over wet ice. Following decellularization (3.3.2), 
the tissue was subjected to elastase treatment (10 u/mL). Figure 8 shows the process of 
forming the valve from these scaffolds. To form the tri-layered valves, silicon molds and 
counter molds were made from aortic valves. Those counter molds were then used to 
shape the collagen pericardium scaffolding into aortic roots and leaflets. After cross-
linking (3.3.3) of the new valve, the original leaflets of the valves were removed and the 
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scaffolds were then sutured to the original aortic root from where it was created, forming 
the ventricularis and fibrosa layers of an aortic tricuspid valve. 
Cellular specifications 
 Following a rinsing, the valve and external pulmonary scaffold were neutralized 
(3.3.4) and each pulmonary artery scaffold was seeded with 5E4 human bone marrow-
derived stem cells. Figure 7 shows the pulmonary scaffold after insertion between the two 
layers of pericardium scaffolding, which were later glued together to form the pocket. 
After one night in the bioreactor, a leaflet that was impeding the opening and closing of 
the other two was dissected and its spongiosa layer was placed in a six-well plate as a 
static control. 
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Figure 7: Cross sectional view of 
the tri-layered leaflet. 
(Courtesy of Dr. Dan  Simionescu) 
 
 
Figure 8: Formation of the tissue engineered heart valve. (a-d) silicon molds and counter-molds 
made from aortic valves. (e-i) layered collagen scaffolds shaped as aortic roots. (j) Aortic root 
constructs were cut open to show internal structures. Final construct was prepared by gluing layers at 
the cusp levels (k), welding free edges (m) and suturing above the sinuses (n). Gluing and welding 
were done here only for demo purposes (see next steps). The construct was then sutured to the 
original aortic root (from which the silicon mold was created) maintaining the proper orientation (o); 
cell-seeded spongiosa was then placed between the two fibrous layers (p), the cusp edges sealed with 
glue (q) and the aortic root closed and rinsed for implantation into the heart valve bioreactor (r). 
(Data and photos courtesy of Dr. Dan  Simionescu and Mary E. “Betsy” Tedder) 
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Bioreactor conditions 
 The valve was mounted into the bioreactor in DMEM with 10% fetal bovine 
serum and 1% antibiotics/antimycotics and progressive adaptation over a time period of 
three days was used to bring the pumping conditions to 60 bpm, 33% inspiration time, 
and approximately 18 mL per stroke. Media in the bioreactor was not changed, but media 
in the static control was changed every three days. The static control was placed in the 
incubator next to the bioreactor at 37°C and 5% CO2
Analysis 
. 
 After a test period of eight days, the spongiosa layers of the valves were analyzed 
according to the assays listed in Table 5. 
Table 5: Experimental conditions & assays for tri-layered tissue engineered heart valve 
(3.4.4). 
V
al
ve
 
C
us
p 
Se
ct
io
n 
Number 
of Days 
Conditioning specifications 
Assay Performed beats 
per 
minute 
stroke 
volume 
(mL) 
°C 
% 
CO
2 
TE
H
V
 
1 
a 
8 60 18 37 5 
Live/Dead 
b DAPI 
c DAPI + Vimentin 
TE
H
V
 
2 
a 
8 60 18 37 5 
Live/Dead 
b DAPI 
c DAPI + Vimentin 
TE
H
V
 
3 
a 
8 0 0 37 5 
Live/Dead 
b DAPI 
c DAPI + Vimentin 
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CHAPTER 4: RESULTS 
4.1 Bioreactor Design 
 A pneumatic-driven conditioning system (Figure 9), was developed that consists 
of a three-chambered heart valve bioreactor (1), a webcam for viewing (2), a pressurized 
compliance tank (3), a reservoir tank (4), one-
 
way valves (5), pressure-retaining valves 
(6), pressure transducers (not shown), an air filter for gas exchange (7), and a pump 
(Siemens 900E) to power the cyclic fluid flow (8). The acrylic bioreactor can be 
sterilized using conventional methods and accommodates all clinically relevant sizes of 
stented or stentless biological, mechanical or tissue engineered substitutes. Other features 
of the bioreactor include an unobstructed observation area for the camera, a modular 
design allowing easy replacement of cell culture media, and multiple ports for media 
sampling. 
Figure 9: Culture system schematic 
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 The developed bioreactor seen in Figure 10 is composed of three transparent 
compartments. Made of acrylic plastic, it is 6 inches in diameter, approximately 8.5 
inches tall, and completely transparent. The three parts of the bioreactor are held together 
by stainless steel screws. 
 The air chamber (A) is connected to the external pump and is the only chamber 
not filled with culture medium. It is separated from the pumping chamber (B) by clear 
silicone rubber. Through the power of the external air pump, this membrane bulges into 
the pumping chamber and pushes the residing media through the heart valve (C) into the 
aortic chamber (D). Once completed, the pump releases pressure in the air chamber, 
allowing the membrane to fall down and draw culture medium in through the one way 
valves from the reservoir tank to fill the pumping chamber in preparation for the next 
cycle. Figure 11 demonstrates this pumping action. 
 During the pumping phase, the curvature of the pumping chamber and angle of 
media inlets ensures consistent distribution of culture medium throughout the chamber. 
Once through the valve, the medium enters the aortic chamber then flows into the 
compliance chamber. The clear, flat top of the aortic chamber facilitates the viewing of 
the functioning of the heart valve. Both the aortic and pumping chambers have multiple 
ports for easy access of pressure transducers, media in/outlets, or other probes. 
 The special removable valve holder in the design is able to adapt to valves of all 
sizes and types. The holder is mounted to the inferior side of the aortic chamber with 
stainless steel screws. With the addition of a sealing cover, the aortic chamber has the 
additional benefit of creating a sterile chamber that can be used to transport the valve. 
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Figure 10: Picture and computer aided drafting representation of assembled bioreactor. 
 
Figure 11: Cross-sectional view of the bioreactor demonstrating the pumping actions. 
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4.2 Bioreactor Capabilities Testing Using a Bioprosthetic Heart 
Valve 
 The desired environmental conditions of the bioreactor as a pump included 1) 
aortic systolic/diastolic pressures reaching at least 120/80 mmHg, 2) flow rates reaching 
5000 mL/min, 3) stroke rate exceeding 60 beats per minute, 4) oxygen and carbon 
dioxide levels appropriate to support the growth of the cells and tissues, and 5) 
repeatability of these conditions. 
 Testing the conditioning system design revealed that most of these conditions 
were met. Sections 4.2.1 and 4.2.2 show r
4.2.1 Pressure 
esults related to the desired pressures and flows, 
respectively. 
 Section 3.2.1 describes the setup for pressurizing the system. Under these 
conditions, values of pressure were recorded under no pressurization, after an initial 
pressurization of the top reservoir using compressed air, after a second pressurization of 
the top reservoir, and after all pressure was released from the system in both the aortic 
chamber and ventricular chamber of the bioreactor. Figure 12 illustrates pressures 
experienced in this experiment. Figure 13 details the non-pressurized section and Figure 
14 shows the sustained pressurized section. Figure 12 and Figure 13 reveal the effects of 
taking readings through the DAQ at 180 Hz. Only three data points were plotted per 
second, creating a “low resolution” pressure profile. 
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Figure 12: Chamber pressures. a) no added pressure b) initial pressurization c) additional pressurization 
d) release of all pressure 
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Figure 13: Chamber pressures without external application of pressure 
 
 
 
Figure 14: Chamber pressures with external application of pressure 
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4.2.2 Flow 
 As section 3.2.2 described, fluid flow through the system was measured at 
increasing, incremental values. Table 6 shows the resulting stroke volumes at 60 bpm for  
as the value of inspiration tidal volume of air (mL) set for the ventilator is increased. As a 
result, the total volume of fluid flow per minute ranges from 284 mL/min to 1336 
mL/min. Of note is that for inspiration tidal volume air settings of 7.5 and 10 mL, the 
BHV was only slightly opening. Figure 15 shows a graphical representation of the same 
data, that can be used to find the ventilator settings necessary to achieve a desired stroke 
rate. Figure 16 shows the same for the total fluid flow per minute. 
Table 6: Stroke volumes at 60 
beats per minute 
Inspiration Tidal 
Volume Air (mL) 
Stroke 
Volume (mL) 
7.5* 4.7 
10* 6.2 
20 8.6 
50 14.3 
80 17.5 
100 18.7 
130 22.3 
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Figure 15: Stroke volume for multiple settings of the ventilator. Use this graph to determine how to 
set the the air stroke volume on the ventilator for a desired fluid stroke volume through the valve. 
 
 
 
Figure 16: Total fluid flow through the valve per minute. 
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4.3 Heart Valve Experimentation 
 Fifteen experiments tested four types of valves. The first was a living valve that 
was mounted within hours of harvesting. The second and third valves were decellularized, 
fixed, and seeded with either porcine aortic endothelial cells or rat adipose-derived stem 
cells, respectively. The fourth valve was made of decellularized, fixed, 
 
  
valve-shaped 
fibrous sheets encasing a spongy collagen scaffold seeded with human bone marrow-
derived stem cells. Figure 17 shows macroscopic images of these valves with a summary 
of the experimental conditions for each. The bioreactor successfully maintained an 
environment conducive to cell survival and differentiation. It provided the desired factors 
for the desired amount of time. Figure 17 shows an overview of each valve and detailed 
results for each valve type are below. 
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4.3.1 Valve 1: Living Valve – 7 Days 
 Visual analysis of the Diff-Quick staining revealed that the cells were less dense 
in the dynamic cusp than in the static cusp. Live/DEAD imaging revealed similar 
numbers of live cells between the two groups. However, a slightly higher number of dead 
cells were present in the dynamic cusp than in the static cusp. Figure 18 shows 
representative images of the Diff-Quick and Live/DEAD assays.  
 Table 7 shows the MTS assay supporting these findings in both the static and 
dynamic cusps. The increase in the cell solution’s optical density (OD) after the 
incubation period in both the static and dynamic cusps signified the presence of living, 
metabolically active cells, but corresponding to the visual analysis of the Live/DEAD and 
Diff-Quick assays, the OD of the dynamic cusps was 15% lower than that of the static 
cusps. 
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Figure 18: Results of the living valve experiment, 7 days. 
Diff-Quick,  nucleus = blue, cytoplasm = red/pink; Live/DEAD, live  = green, dead = red. 
Table 7: Optical density of culture solution via MTS assay. 
  
Optical Density Wet Weight Mean OD 
per mg Wet 
Standard 
Deviation 
OD per Avg Cusp 
Weight = 50mg Cusp 1 Cusp 2 Cusp 1 Cusp 2 
T7-Static 2.88 2.13 71.04 50.27 0.0414 0.00122 2.07 
T7-Dynamic 1.50 1.44 40.58 42.19 0.0355 0.00190 1.77 
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4.3.2 Valve 2: Endothelial Cell Seeded Valve – 21 Days 
 Figure 20 and Figure 22 provide results from this experiment at time = 0 days. 
Figure 21 and Figure 23 reveal the results at time = 21 days. Histological sections show 
successful initial decellularization in all samples. Cells were successfully seeded and cells 
remained present on all appropriate groups for the entire experiment. While some cellular 
alignment is in all groups, there is notably more in the valve under dynamic conditions 
than in any other valve. SEM imaging revealed that most cells were located near the base 
of the cusp rather than near the free edge of the cusp. SEM imaging identified significant 
morphological, alignment, density, and locational differences. 
 Inspecting the solution of Live/DEAD stain used for the time = 21 days revealed 
many cells present in that solution after transferring the cusp. Figure 19 shows this 
solution and the cells that detached during manipulative handling. 
 
Figure 19: Live/DEAD staining solution. 
Live/DEAD, live  = green, dead = red. 
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Figure 20: Results of the endothelial cell experiment, 0 days. 
Live/DEAD, live  = green, dead = red.; DAPI, nucleus = blue. 
For ease of viewing, digitally altered images of DAPI staining can be found in Appendix B 
(DAPI staining & photos courtesy of Mary E. ”Betsy” Tedder)  
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Figure 21: Results of the endothelial cell experiment, 21 days. 
Live/DEAD, live  = green, dead = red.; DAPI, nucleus = blue. 
For ease of viewing, digitally altered images of DAPI staining can be found in Appendix B 
(DAPI staining & photos courtesy of Mary E. ”Betsy” Tedder) 
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Figure 22: SEM images from the endothelial cell experiment, 0 days, no cells, static. 
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Figure 23: SEM images from the endothelial cell experiment, 0 days, cells, static. 
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Figure 24: SEM images from the endothelial cell experiment, 0 days, cells, static. 
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Figure 25: SEM images from the endothelial cell experiment, 21 days, cells, static. 
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Figure 26: SEM images from the endothelial cell experiment, 21 days, cells, static. 
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Figure 27: SEM images from the endothelial cell experiment, 21 days, cells, dynamic. 
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Figure 28: SEM images from the endothelial cell experiment, 21 days, cells, dynamic. 
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4.3.3 Valve 3: Adipose-derived Stem Cell Seeded Valve – 21 Days 
 Figure 29 reveals histological sections show successful decellularization of the 
cusps in this experiment. The yellow arrows notes the presence of seeded cells at time = 
21 days. DAPI imaging confirmed the presence of cells at time = 21 days in the H&E 
sections. 
 
Figure 29: Results of the adipose-derived stem cell experiment, 21 days. 
Live/DEAD, live = green; DAPI, nucleus = blue.  
For ease of viewing, digitally altered images of DAPI staining can be found in Appendix B 
Live/DEAD staining & photos courtesy of Dr. Aggie Simionescu and Christopher Albers) 
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4.3.4 Valve 4: Tri-layered Tissue Engineered Heart Valve – 8 Days 
 Figure 31 shows that human bone marrow-derived cells survived on the spongiosa 
layer of the tissue engineered heart valve in static and dynamic conditions for eight days. 
Cells in the dynamic conditions of the bioreactor were more elongated and stained more 
heavily for vimentin than those under static conditions. For comparison, Figure 30 
includes images of porcine valvular interstitial cells stained for vimentin (red) and 
smooth muscle cell actin (red). 
 
Figure 30: Actin vs. vimentin in valvular insterstitial 
cells for comparison. 
actin = red, nucleus = blue, vimentin = red. 
(Staining & photos courtesy of Dr. Dan  Simionescu and 
Mary E. “Betsy” Tedder) 
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Figure 31: Results of the tissue engineered heart valve experiment, 8 days. 
Live/DEAD, live = green; DAPI, nucleus = blue; Vimentin, nucleus = blue, vimentin = red. 
(Staining & photos courtesy of Dr. Dan  Simionescu and Mary E. “Betsy” Tedder) 
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CHAPTER 5: ANALYSIS AND DISCUSSION 
5.1 Bioreactor Design 
 The final product demonstrates that the objectives and wants of the customer were 
routinely reviewed during the design process to ensure that they were followed. The 
valve successfully opened and closed in every experiment, the system enabled pressures 
to be easily altered, and flow was adequate to ensure proper nutrient and waste transport. 
Throughout the project, the bioreactor was consistent, reproducible, non-toxic, and 
maintained the visibility of the heart valve using a webcam, which broadcasted the 
playback on the internet.  
 Unlike other heart valve bioreactors in the literature, the Clemson heart valve 
bioreactor is able to test all clinically relevant sizes of stented or stentless biological, 
mechanical, or tissue engineered valve substitutes. It’s variable mounting method can 
adjust for variant thicknesses of the base, rigidities of the aortic root, and even amounts 
of material that would normally be used for mounting. Throughout the fifteen pilot tests, 
each variance in valves was seen and mounted at least once.  
 The greatest weakness of the Clemson bioreactor its ability to maintain a sterile 
environment. The large number of pieces, time it takes to assemble, and frequent media 
changes all contribute to the risk of contamination. Eventually, as we learned how to 
properly handle, assemble, and change media in the bioreactor, sterility problems 
occurred less often. We considere this hindrance solved, as the last set of experiments 
performed had no contamination present.   
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5.2 Bioreactor Capabilities Testing Using a Bioprosthetic Heart 
Valve 
 The final design of the bioreactor system is able to achieve the desired 
environmental conditions, but it does not reach all the goals given in the revised client 
statement for it’s qualities as a pump. It supplied the physiological conditions of cyclic 
opening and closing, nutrient content, and stroke rate. However, the bioreactor system 
was unable to achieve a flow rate of up to 5000 mL/min or pressures reaching 120/80 
mmHg. The flow rate and pressures it reached were approximately 1350 mL/min and 
100/70 mmHg, respectively. These values are not quite physiological, but they are 
comparable to those of many other bioreactor designs. By using an alternative pumping 
mechanism, modifications could be made to increase these values. 
 Flow rate and pressure do not yet meet physiological levels, but at the current 
stage of tissue engineering, this is not an issue. Current tissue engineered heart valves 
must go through steps of progressive adaptation, with flow and pressure beginning at 
values much lower than those that the Clemson bioreactor can reach. As the technology 
improves and valves get closer to implantation, we will need to be able to reach the 
higher values to represent physiological conditions, but for now the current maximum 
values are more than adequate to for the initial stages of tissue engineered heart valve 
development. 
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5.3 Heart Valve Experimentation 
 The four valve experiments shown of the fifteen performed were a wide 
demonstration of the bioreactor’s capabilities, from keeping living tissue alive, to the 
differentiation of stem cells. These tests adequately show the functionality of the 
designed heart valve bioreactor. 
 Many of the cells on the living valve were still viable after one week under static 
conditions and in the bioreactor. Extended experiments will help determine the different 
effects of static and dynamic culture on cell viability, but these results are useful to show 
that the bioreactor is capable of supporting cellular life in large quantities of culture 
media with the closest air-media interface occurring more than 20 cm away. 
 The endothelial cell seeded valve experiment was successful in many 
ways. 
 Live/DEAD imaging of the dynamic cusp surfaces showed cellular alignment 
around certain structures believed to be the large collagen bundles present in the cusp’s 
circumferential direction. Scanning electron microscopy (SEM) confirmed and 
strengthened this finding, revealing some alignment on the static cusp, but notably greater 
alignment on the dynamic cusp. Also of note is that on the dynamic valve, the cells on 
Histological sections of the non-seeded valve demonstrated efficacy of the 
decellularization method. Endothelial cells initially attached to the valve surfaces and 
remained for 21 days under both static and dynamic conditions, but the differences 
between the cells subjected to those conditions are great. Though we were unable to 
quantify cell proliferation, we saw more cells present and alive in the dynamic conditions 
than in the static conditions after 21 days.  
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“top” of the collagen bundles were lined up in the circumferencial direction of the bundle 
while the cells on the base or in the “valleys” of the bundles were often lined up in the 
longitudinal direction of the bundles. 
 Perhaps the most apparent difference between the cells on the static valve with the 
cells on the dynamic valve was the morphology. SEM was crucial in these findings. Cells 
under static conditions for 21 days were often flattened and fairly dendritic. Cells under 
dynamic conditions for 21 days were either flattened or more rounded, but did not exhibit 
dendritic structures to the same extent as the cells under static conditions. 
 After analyzing the solution of Live/DEAD stain for the 21-day valves we found 
that many cells were lost during the transfer of the cusp from the staining solution to the 
imaging well. This suggests a greater number of cells present on the cusps than the 
Live/DEAD images present. It also suggests that seeded cusps are sensitive to handling 
and future experiments should use a “no-touch” technique for all tissue handling to 
prevent sloughing off of any cells. 
 The adipose-derived stem cell seeded valve showed that stem cells would 
remain on the cusp scaffolds for three weeks. DAPI confirmed the presence of these 
seeded cells on the static and dynamic valve. 
 Human bone marrow-derived stem cells expressed signs of differentiation after 
just 8 days in the bioreactor that were not present to the same extent in the static control. 
The cells’ expression of vimentin demonstrates that the stem cells had differentiated into 
a fibroblast-like phenotype. Vimentin is also one of the markers used to identify valvular 
interstitial cells, which resemble both smooth muscle cells and fibroblasts. This implies 
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that the bioreactor is aiding the differentiation of these cells into cells that resemble 
valvular interstitial cells. 
 Overall, results indicated successful cell seeding and attachment in all appropriate 
valves, noticeable intercellular alignment in the seeded valves, and stem cell 
differentiation in the human bone marrow-derived stem cell seeded valve. The 
conditioning system provides a dynamic, three-dimensional cell culture setting to provide 
optimal physiological conditions for tissue engineered heart valve development over 
extended periods. This approach will be further developed to study multiple aspects of 
tissue engineered heart valve development and heart valve pathology. 
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CHAPTER 6: CONCLUSIONS 
1) The bioreactor is adaptable for any clinically relevant valve and caused all types of 
heart valves to cyclically open and close. 
2) Flow, pressure, and stroke rate can be controlled and reproduced in the bioreactor. 
Though they do not reach physiological levels, conditions of flow and pressure 
achieved are adequate for conditioning tissue engineered heart valves. 
3) The treated surface of the decellularized, fixed, and neutralized valves was 
compatible with porcine aortic endothelial cells, rat adipose-derived stem cells, and 
human bone marrow-derived stem cells. 
4) Cell viability can be maintained in the bioreactor for at least three weeks, as 
demsonstrated with four cell types, including native cells. 
5) The bioreactor creates adequate force vectors to induce cell alignment on the cusps. 
6) The bioreactor is able to induce differentiation of stem cells into fibroblast-like cells. 
 
Results show that the bioreactor is able to provide cell-friendly conditions and 
create forces on the heart valve cusps, creating a controllable environment that will 
be necessary in the conditioning of tissue engineered heart valves. 
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CHAPTER 7: RECOMMENDATIONS 
1) The next step that should be taken to improve this bioreactor is to increase the sample 
size so multiple valves can be tested concurrently. This will be important when 
statistically significant data is necessary. A multiple valve bioreactor should be 
designed in the near future. 
2) Improving the flow rates and pressures is also important to be able to reach and 
exceed the native physiological resting conditions. A different type of pumping 
mechanism such as a CAM driven device might be necessary instead of a pneumatic 
pump. 
3) An improved method of assembling the bioreactor and changing the culture media 
should be investigated. This would create less opportunity for intial contamination 
and allow the experiments to run longer with less risk of contamination. 
4) A long term experiment should be performed with stem cells to examine the self-
repairing capabilities of tissue engineered heart valves. 
 
The bioreactor approach should be continually developed to study multiple aspects 
of tissue engineered heart valve development and heart valve pathology. 
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Appendix A: Design Documentation 
Client Questionnaire 
 
1) How is the bioreactor to be used? 
 - to test function? 
 - to condition? 
 - to measure mechanical properties? 
 - to transport a finished product to the hospital for implantation? 
 - to provide information regarding formation process of 3D tissues 
 - to provide information regarding development of the cells 
 - to establish a uniform distribution of cells on a 3D scaffold/facilitate cell seeding 
 - other? 
 
2) What mechanical forces will be important to measure? 
 - shear stress 
 - fluid speed 
 - fluid density 
 - pressure drop across tissue 
 - total pressure magnitudes 
 - pressure waveform 
 - negative pressure anywhere 
 - flow waveform 
 - flow rate 
 - stroke volume 
 - frequency 
 - other 
 
3) What mechanical forces will be important to regulate? 
 - shear stress 
 - fluid speed 
 - fluid density 
 - pressure drop across tissue 
 - total pressure magnitudes 
 - pressure waveform 
 - negative pressure anywhere 
 - flow waveform 
 - flow rate 
 - stroke volume 
 - frequency 
 - other 
 
4) How many samples would you like to run at once? 
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5) What is your estimate of what the cost should be? 
 
6) What is the maximum amount of money you would like to spend, if known? 
 
7) What types of sterilization are available on campus? 
 
8) What nutrients will be important to measure? 
 - O2 (pO2) 
 - CO2 (pCO2
9) What nutrients will be important to regulate? 
) 
 - glucose 
 - temperature 
 - pH 
 - other 
 
 - O2 (pO2) 
 - CO2 (pCO2
10) How many days should the system be able to run? 
) 
 - glucose 
 - temperature 
 - pH 
 - other 
 
 
11) What methods of attachment of the tissue to the bioreactor are possible or preferred? 
 
12) How well do gasses and nutrients / wastes diffuse through the pericardium and other 
material used? How thick is the material to be used? 
 
13) What will the shape of the “heart valve” be? OR: What are the sizes of the vascular 
grafts? 
 - leaflets only 
 - leaflets with some aorta 
 - leaflets on a ring 
 - leaflets with aorta and something on other side 
 - other 
 
14) What diameter tissues will be used 
 
15) How much user interaction/manipulation is acceptable? 
 - all computer controlled 
 - adjust valves with a screwdriver 
 - automatic measurements vs. computer-controlled readings 
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16) What type of cells or other materials will be used and what are their mechanical and 
chemical / nutritional requirements? 
 
17) What are the values you would like to have available for mechanical forces? 
 - embryonic conditions 
 - newborn conditions 
 - slow then increase in pressure and flow rate 
 - values in numbers… 
 - other 
 
18) What are the values you would like to have available for nutrient levels? 
 - embryonic conditions 
 - newborn conditions 
 - increasing with time 
 - values in numbers… 
 - other 
 
19) Should the forces in the radial, circumferential, and longitudinal directions vary? If so, 
how? 
 
 
20) Are there any other comments, wishes, or suggestions you wish to see implemented 
in the design of this first phase of the bioreactor? This is a chance for you to tell me 
what YOU want out of the bioreactor if I have missed anything in the previous 
questions. Please, give me input. 
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Attributes List 
Provide physiological pressure 
Provide physiological flow of nutrient medium 
Be contamination-resistant 
Be maximally sterile 
Have adjustable pulsatile flow (50-2000 mL/min) 
Have varying levels of pressure (10-240 mmHg) 
Be compact 
Fit inside an incubator 
Provide optimal gas supply 
Provide stable temperature 
Provide “instantaneous” flow of fluid through material to be tested – flow waveform 
Have adjustable stroke volume of ventilator 
Have adjustable ventilation rate of ventilator 
Expose developing tissue to “correct” physiological “signals” 
Allow long term testing 
Be (largely) self reliant (Utilized with additional sophisticated equipment) 
Be very robust 
Be easy to clean and sterilize (ethylene oxide?) 
Be transparent 
Allow easy attachment of valve to system 
Test up to ~10 samples at one time 
Provide flow conditions similar to those of natural heart valves 
Establish a uniform distribution of cells on a 3D scaffold 
Maintain desired concentration of gases and nutrients in culture medium 
Provide efficient mass transfer to the growing tissue 
Expose developing tissue to physical stimuli 
Provide information regarding formation process of 3D tissues, which originate from the 
isolated cells 
Control biomechanical environment 
Control biochemical environment 
Control pH 
Control O2 (pO2) 
Control CO2 (pCO2) 
Control glucose 
Be basic / not complicated / simple 
Fluid flow: composition, flow rate, pressure, temperature (heat supply) 
Mechanical force: pulsatile forces, pressure, flow rate, shear stress, frequency, stroke rate, 
stroke volume 
Be adaptable to multiple cardiovascular applications 
Be user friendly 
Be time efficient 
Have quick setup 
Be repeatable  
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Objectives, Functions, and Constraints Lists 
Objectives: 
Should be compact / small 
Must be very robust / durable 
 Should be made of durable materials 
 Machinery should be of good quality 
 Must be repairable 
  Must be able to separate into individual parts 
  Parts must be replaceable 
Should be adaptable to multiple cardiovascular applications 
 Tissue-mount should be changeable for different tissues 
 Tissue-mount should be adjustable for different sizes and variations of tissue 
 Applied forces should be adjustable 
 Nutrient / waste levels should be adjustable 
Should be user friendly 
 Should be basic / simple 
  Should have few parts requiring multiple adjustments 
  Should have few components 
 Should be time efficient 
  Should have quick setup 
  Should have easy setup 
 Should facilitate easy attachment of cardiovascular construct to the system 
 Should be (largely) self reliant (little manual work by user required to change 
settings – screwdriver adjustments OK) 
Must be repeatable 
Must be sterile 
 Must be sterilizible (ethylene oxide?) 
 Must be contamination-resistant 
 Should be transparent 
 Should be easy to clean 
Should be affordable to produce ($2500-$5000) 
 
Constraints: 
Must fit inside an incubator (how of controlling temp and pH) – means of the function 
Must cost less than ~$5000 
Material must not degrade in the presence of liquids 
 
Requirements: 
Vascular size changes monitored by video image capture 
Minimize medium volume 
Change medium in a sterile manner 
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Functions: 
Provide information regarding formation process of 3D tissues (visually see 3D structure) 
Facilitate cell seeding and establish a uniform distribution of cells on a 3D scaffold (cells 
may be placed on scaffold after scaffold is attached to incubator) 
Test function the cardiovascular tissue (open and close heart valve or pump fluid through 
vascular graft) 
Hold 3-6 samples at once 
Condition cardiovascular tissues for both 2-3 weeks and 5-6 months (why of 
maintaining sterility) 
Hold the cardiovascular tissue being tested 
Display all settings and levels in a compact and understandable manner 
 
Provide proper nutrient and waste transport to and from the tissue (pediatric conditions 
for valves, adult for grafts) 
 Maintain temperature at 37°C (incubator) 
 Maintain pH at 7.2-7.4 (incubator / CO2) 
  Control CO2 (pCO2) (incubator) 
 Maintain high levels of O2 (pO2) (~20%?) 
 Control glucose levels 
 
Apply proper forces to a cardiovascular tissue (pediatric conditions for valves, adult for 
grafts) 
 Control pressure waveform over cardiac cycle 
 Control pressure drop across tissue (160/100 mmHg for heart valve) 
 Control flow waveform over cardiac cycle 
 Control flow rate (50-2000 mL/min?) 
  Control stroke volume 
  Control frequency (60-70 bpm) 
 Control shear stress 
  Control fluid speed 
  Control fluid density 
   Controlling fluid composition 
 
Measure forces to cardiovascular tissue 
 Pressure drop across tissue 
 Pressure waveform over cardiac cycle 
 Flow rate 
  Stroke volume 
  Frequency 
 Shear stress 
  Fluid speed 
  Fluid density 
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Pair-wise Comparison Charts 
 
Dan, Aggie, Betsy, and Tom, 
 
 
On the following charts, please compare the items in the left column to each item in the 
top row, deciding which one is a more important quality for the bioreactor to have. These 
are very broad and basic goals/objectives that the bioreactor is to achieve. Some are more 
important than others and this will help me focus on what you believe to be the most 
important areas. 
 
 
I included a “tree” to help you visualize which goals are sub-goals, etc. 
 
 
Scoring: 
 
Item in left column is more important than item in top row: 1 
Item in left column is equally important as item in top row: 0.5 
Item in left column is less important than item in top row: 0 
 
Do not fill in the gray boxes (they are duplicates of the white boxes) 
 
 
 
This is only to get your views on RELATIVE importance 
 
 
Thank you, 
Lee 
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Main Objectives 
Objectives PCC Compact or Small Durable
Adaptable to 
Multiple 
Cardiovascular 
Applications
User 
Friendly Repeatable Sterile
Affordable 
to Produce Total
Compact or 
Small XXXX 0 2 1 1 1 1 6
Durable 3 XXXX 3 2 1 2 4 15
Adaptable to 
Multiple 
Cardiovascular 
Applications
2 0 XXXX 1 0 0 1 4
User Friendly 3 1 3 XXXX 0 2 2 11
Repeatable 3 3 4 4 XXXX 3 4 21
Sterile 3 1 3 2 1 XXXX 3 13
Affordable to 
Produce 3 0 3 2 0 1 XXXX 9
Repeatable 
Durable 
Sterile 
User Friendly 
Affordable 
Compact 
Adaptable 
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Sub-objective: Durable 
Durable Made of Durable Materials
High Quality 
Machinery Repairable Total
Made of Durable 
Materials XXXX 1 1 2
High Quality Machinery 0 XXXX 1 1
Repairable 2 2 XXXX 4
 
Repairable 
Durable materials 
High quality machinery 
 
Sub-sub-objective: Repairable 
Repairable
Able to be 
separated into 
multiple parts
Replaceable 
parts Total
Able to be separated 
into multiple parts XXXX 0 0
Replaceable parts 1 XXXX 1
 
Replaceable parts 
Able to be separated 
 
Sub-objective: Adaptable to multiple cardiovascular applications 
Adaptable to multiple 
cardiovascular 
applications
Changeable 
tissue-mount for 
different tissues
Changeable tissue-mount 
for different sizes and 
variations of tissue
Adjustable 
applied forces
Adjustable 
nutrient and 
waste levels
Total
Changeable tissue-mount 
for different tissues XXXX 0 1 1 2
Changeable tissue-mount 
for different sizes and 
variations of tissue
3 XXXX 1 2 6
Adjustable applied forces 3 3 XXXX 3 9
Adjustable nutrient and 
waste levels 3 0 0 XXXX 3
Adjustable applied forces 
Changeable tissue shapes and sizes 
Adjustable nutrient and waste levels 
Changeable tissues 
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Sub-objective: User friendly 
User Friendly Basic / simple Time efficient
Facilitate easy 
attachment of 
cardiovascular tissue
(Largely) 
self-reliant Total
Basic / simple XXXX 1 0 2 3
Time efficient 2 XXXX 0 2 4
Facilitate easy 
attachment of 
cardiovascular tissue
3 2 XXXX 2 7
(Largely) self-reliant 2 2 2 XXXX 6
 
Easy attachment of tissue 
Self reliant 
Time efficient 
Basic, simple 
 
Sub-sub-objective: Basic / simple 
Basic / not 
complicated / simple
Have few parts 
requiring multiple 
adjustments
Have few 
components Total
Have few parts 
requiring multiple 
adjustments
XXXX 1 1
Have few components 1 XXXX 1
 
Multiple adjustments – Few components 
 
Sub-sub-objective: Time efficient 
Time efficient Quick setup Easy setup Total
Quick setup XXXX 1 1
Easy setup 2 XXXX 2
 
Easy setup 
Quick setup 
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Sub-objective: Sterile 
Sterile Sterilizible Contamination-resistant Transparent
Easy to 
clean Total
Sterilizible XXXX 1 1 1 3
Contamination-
resistant 1 XXXX 0 1 2
Transparent 1 1 XXXX 1 3
Easy to clean 1 0 0 XXXX 1
 
Sterilizible – Transparent 
Contamination resistant 
Easy to clean 
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Main objectives: 
1) Repeatable 
2) Durable 
3) Sterile 
4) User friendly 
5) Affordable 
6) Compact 
7) Adaptable 
 
Sub-objective: Durable 
1) Repairable 
2) Durable materials 
3) High quality machinery 
 
Sub-sub-objective: Repairable 
1) Replaceable parts 
2) Able to be separated 
 
Sub-objective: Adaptable 
1) Adjustable applied forces 
2) Changeable tissue shapes and sizes 
3) Adjustable nutrient and waste levels 
4) Changeable tissues 
 
Sub-objective: User friendly 
1) Easy attachment of tissue 
2) Self reliant 
3) Time efficient 
4) Basic, simple 
 
Sub-sub-objective: Basic / simple 
1) Multiple adjustments – Few components 
 
Sub-sub-objective: Time efficient 
1) Easy setup 
2) Quick setup 
 
Sub-objective: Sterile 
1) Sterilizible – Transparent 
2) Contamination resistant 
3) Easy to clean 
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Appendix B: Digitally Inverted DAPI Images 
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